FGFR inhibitor · small molecule
tasurgratinib
1 active trials across 2 of our biomarkers, targeting FGFR1-3. Not approved for any biomarker on marked.bio yet.
Also known as E7090.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| FGFR3 alteration (mutation or fusion) | 1 | 1 | Phase 2 |
| FGFR2 fusion or rearrangement | 0 | 1 | – |
Trials
1 of 2 trials shown
-
NCCH2006/MK010 Trial (FORTUNE Trial)
Participants with an FGFR gene alteration detected by NGS panel, who fall under one of the categories of groups A to C and E define…
FGFR3 alteration (mutation or fusion)Advanced or Recurrent Solid Tumors, FGFR Gene Alterations
-
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
Participants who have confirmed FGFR2 gene fusion of tumor by fluorescence in situ hybridization (FISH) in central laboratory.
FGFR2 fusion or rearrangementCholangiocarcinoma
No trials match these filters.